Faecal metronidazole concentrations during oral and intravenous therapy for antibiotic associated colitis due to Clostridium difficile.
about
Clostridium difficile: its disease and toxinsSusceptibility testing of Dientamoeba fragilis ATCC 30948 with iodoquinol, paromomycin, tetracycline, and metronidazoleRecent advances in the understanding of antibiotic resistance in Clostridium difficile infectionClostridium difficile Infection in Children: Current State and Unanswered QuestionsAntimicrobial Resistance and Reduced Susceptibility in Clostridium difficile: Potential Consequences for Induction, Treatment, and Recurrence of C. difficile InfectionThe changing epidemiology of Clostridium difficile infectionsClostridium difficile infection: New insights into therapeutic options.Clostridium difficile infection: guideline-based diagnosis and treatmentIdentification of risk factors for the development of clostridium difficile-associated diarrhea following treatment of polymicrobial surgical infections[Current data and trends on the development of antibiotic resistance of Clostridium difficile].Antimicrobial susceptibilities and serogroups of clinical strains of Clostridium difficile isolated in France in 1991 and 1997.Reassessment of Clostridium difficile susceptibility to metronidazole and vancomycin.Clostridium difficile colitis: a review.Clostridium difficile infection in patients with neutropenia.Characterization of a stable, metronidazole-resistant Clostridium difficile clinical isolateA comparison of vancomycin and metronidazole for the treatment of Clostridium difficile-associated diarrhea, stratified by disease severity.Antimicrobial susceptibilities and molecular epidemiology of clinical isolates of Clostridium difficile in taiwan.Treatment of Clostridium difficile-associated diarrhea.Defining the vulnerable period for re-establishment of Clostridium difficile colonization after treatment of C. difficile infection with oral vancomycin or metronidazoleA randomised phase 1 study to investigate safety, pharmacokinetics and impact on gut microbiota following single and multiple oral doses in healthy male subjects of SMT19969, a novel agent for Clostridium difficile infections.Future novel therapeutic agents for Clostridium difficile infection.Clostridium difficile Infection and Inflammatory Bowel Disease: A Review.Vancomycin Enemas as Adjunctive Therapy for Clostridium difficile Infection.Differences of the Fecal Microflora With Clostridium difficile Therapies.Clostridium difficile drug pipeline: challenges in discovery and development of new agentsProspective observational study comparing three different treatment regimes in patients with Clostridium difficile infection.Clostridium difficile-associated colitisFidaxomicin attains high fecal concentrations with minimal plasma concentrations following oral administration in patients with Clostridium difficile infection.Treatment of Clostridium difficile infection in mice with vancomycin alone is as effective as treatment with vancomycin and metronidazole in combinationSusceptibility of Clostridium difficile isolates from a Phase 2 clinical trial of cadazolid and vancomycin in C. difficile infectionClostridium difficile: an emerging pathogen in children.Both oral metronidazole and oral vancomycin promote persistent overgrowth of vancomycin-resistant enterococci during treatment of Clostridium difficile-associated diseaseClostridium difficile: recent epidemiologic findings and advances in therapy.Clostridium difficile infections in a Canadian tertiary care hospital before and during a regional epidemic associated with the BI/NAP1/027 strain.The ecology and pathobiology of Clostridium difficile infections: an interdisciplinary challengeEffect of Surotomycin, a Novel Cyclic Lipopeptide Antibiotic, on Intestinal Colonization with Vancomycin-Resistant Enterococci and Klebsiella pneumoniae in Mice.Emerging therapies for Clostridium difficile infection - focus on fidaxomicin.Rifamycin antibiotics for treatment of Clostridium difficile-associated diarrhea.Clostridium difficile infection in the intensive care unit.Treatment Strategies for Recurrent Clostridium difficile Infection.
P2860
Q24617347-0077255C-6E52-43DF-BF68-E82DC23B169DQ24679749-C12106B9-FA34-4064-BBF6-C0D4218E5C46Q26767079-E1C17DB6-7D4A-4E72-81BB-04BB750ED8FDQ27016320-2CB8E75C-604C-438D-84AE-F628C6427BEAQ28084026-61150C0E-DE44-4AA7-B1A0-2778ABD1A0F3Q28750385-53BC618A-45F7-4E4C-AFF0-4F0B31FDA9A1Q30252154-A540B743-BE9B-4019-9A4B-201D1644A469Q30316981-8A915961-3857-4D8A-B25B-F0407E8FACB2Q30433267-8E12E877-56D8-447C-B865-40D119D00F81Q30575525-F01FCE5B-A0F4-44DE-B8FF-4EC369E8A505Q30804635-030D85E9-BF7D-4183-9D04-AD4D13D034E6Q34108924-39096BF5-32EE-4351-9366-20A1B1E57E09Q34260389-FA42A692-E8E6-4DA6-A529-5B76B664D7BDQ34340965-36F58666-4B2D-47C2-9AE3-A6CC569B88C0Q34562315-42697F79-4FBB-4FEC-BB45-8876D06CF7AEQ34643123-B0A471DC-C99A-4C51-B1E8-DA4190F67F43Q34737651-35FF5A30-6C82-40A3-BDFC-2CE22DA400FDQ34979678-A8E20097-B661-4756-8D74-E4C6196F9C8AQ35009326-E6E55884-F9F9-4952-8372-9F3DD122A5F0Q35146382-E80ADB75-6BC2-472B-AB58-B57D2DFF0BCEQ35175136-F04EB26A-ADCA-4612-84D5-EDC6BC398F2EQ35208564-BC5C122B-E6E4-4DB8-81B4-2ED8A3F82302Q35387219-4BB6BC4C-6B4F-406B-AEDD-60932D3FBBD0Q35617263-E8971486-5003-4E01-B605-986A2E86681BQ35846436-4DB97AAD-EF18-4688-AC6E-B5523626DD7AQ35867366-C8DC7400-C5C2-43DE-A61A-D9485A757810Q35983360-2E42F1E1-2ED0-47A4-85BC-D3898EB1E222Q36071501-BADA92E9-FDD8-4A00-8C1B-6A1BDE87D9A3Q36270659-7525C98A-318B-46F0-BA3E-FEC199EC6BC0Q36377350-94499D72-4EEC-4097-8D53-A972B51DABECQ36533541-C86BC8CB-1170-4E79-9049-27E10E7B4900Q36744758-31955BA3-C5EC-4749-BA06-49D33F4286B1Q36861661-AD0E1163-150D-4892-892C-1FE74EE2CCB2Q36870734-B0F7BDB5-7F67-46D7-8215-24E4F71D58AFQ36889259-C045B0D9-B9E1-415F-B452-294290079B95Q36933317-04FAB8CB-A65F-404B-B2C1-953109C811D2Q36984883-601B8C97-969F-45E8-950E-225CF1FD334CQ37145568-C2340E12-E541-474F-B328-D414F2D08C3AQ37305032-31934DD0-76A2-41FC-860B-CB5353949914Q37402287-42938F26-BA1A-4C2D-82A0-B542B3956E1D
P2860
Faecal metronidazole concentrations during oral and intravenous therapy for antibiotic associated colitis due to Clostridium difficile.
description
1986 nî lūn-bûn
@nan
1986 թուականի Հոկտեմբերին հրատարակուած գիտական յօդուած
@hyw
1986 թվականի հոտեմբերին հրատարակված գիտական հոդված
@hy
1986年の論文
@ja
1986年論文
@yue
1986年論文
@zh-hant
1986年論文
@zh-hk
1986年論文
@zh-mo
1986年論文
@zh-tw
1986年论文
@wuu
name
Faecal metronidazole concentra ...... due to Clostridium difficile.
@ast
Faecal metronidazole concentra ...... due to Clostridium difficile.
@en
Faecal metronidazole concentra ...... due to Clostridium difficile.
@nl
type
label
Faecal metronidazole concentra ...... due to Clostridium difficile.
@ast
Faecal metronidazole concentra ...... due to Clostridium difficile.
@en
Faecal metronidazole concentra ...... due to Clostridium difficile.
@nl
prefLabel
Faecal metronidazole concentra ...... due to Clostridium difficile.
@ast
Faecal metronidazole concentra ...... due to Clostridium difficile.
@en
Faecal metronidazole concentra ...... due to Clostridium difficile.
@nl
P2860
P356
P1433
P1476
Faecal metronidazole concentra ...... due to Clostridium difficile.
@en
P2093
P2860
P304
P356
10.1136/GUT.27.10.1169
P407
P577
1986-10-01T00:00:00Z